FOR PREVIEW ONLY (Print)

Edwin Posadas, MD

Co-Director, Translational Oncology Program

Co-Medical Director, Urologic Oncology Center

Medical Director, Urologic Oncology Program

Clinical Director, Genitourinary Medical Oncology Program in the Samuel Oschin Comprehensive Cancer Institute

Associate Professor, Medicine

Samuel Oschin Comprehensive Cancer Institute
8700 Beverly Blvd.
Los Angeles, CA 90048

Phone:

310-423-7600

Fax:

310-967-3841

Parking Instructions:

Samuel Oschin Cancer Center parking lot is available on Beverly Blvd.

Edwin Posadas, MD

Co-Director, Translational Oncology Program

Co-Medical Director, Urologic Oncology Center

Medical Director, Urologic Oncology Program

Clinical Director, Genitourinary Medical Oncology Program in the Samuel Oschin Comprehensive Cancer Institute

Associate Professor, Medicine

  • IM/Hematology/Oncology

Adrenal Gland Cancers

Bladder Cancers

Kidney Cancers

Prostate Cancers

Testicular Cancers

Edwin M. Posadas, MD, FACP, is Director of the Translational Oncology Program and the Medical Director of the Urologic Oncology Program at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. He has both clinical and research interests in the treatment of advanced prostate cancer and the biology of cancer metastasis. Posadas is studying the mechanisms through which cancer cells in localized tumors spread to other parts of the body. A protein called FYN, a member of a cancer-causing gene family, was identified in his laboratory as a possible regulator of metastasis and the neuroendocrine phenotype of prostate cancer. Additionally, his laboratory has been studying the role of circulating tumor cells (CTCs) and immune cells (ICs) as biomarkers in prostate and other cancers using novel nanotechnology platforms. His current research interests focus on the most aggressive subtypes of prostate cancer that spread to organs such as the liver and lungs. At Cedars-Sinai, Dr. Posadas is working to define the function of FYN, CTCs, and ICs in prostate cancer, with the goal of applying his basic science findings to the development of new therapies and diagnostic tools that will directly benefit men with advanced prostate cancer. Clinically, he specializes in the use of medical therapies for prostate, kidney, bladder, and testis cancer with an emphasis on integrated, trans-disciplinary care.

View NIH Biographical Sketch as a PDF

  • Medical School: Johns Hopkins School of Medicine, 1998
  • Residency: University of Michigan Medical School, 2001
  • Fellowship: National Cancer Institute, 2005

View CV as a PDF

  • Member, Blood Profiling Atlas in Cancer (BloodPAC). White House Cancer Moonshot Program, 2016
  • Sovereign Military Hospitaller Order of Saint John of Jerusalem of Rhodes and of Malta, 2011
  • Fellow, American College of Physicians, 2010
  • Catholic Medical Association, 2006
  • Society of Basic Urologic Research, 2005
  • American Urologic Association, 2005
  • AACR/NOCC Scholar-in-Training Award, 2004
  • American Association for Cancer Research, 2001
  • Biomedical Engineering Award, 1992
  • Tau Beta Pi National Engineering Honors Society, 1992

Show moreShow less

Click here for a list of peer-reviewed publications.

  • Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM. NanoVelcro chip for CTC enumeration in prostate cancer patients. Methods. 2013;64(2):144-152.
  • Shao C, Liao CP, Hu P, Chu CY, Zhang L, Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, Kim HL, Zhau HE, Chung LW, Wang R, Posadas EM. Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer. PLoS One. 2014;9(2):e88967.
  • Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, et al. miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 2014;20(17):4636-4646.
  • Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, et al. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene. 2015;34(21):2690-2699.
  • Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, et al. miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Clin Cancer Res. 2014;20(24):6559-6569.
  • Posadas EM, Figlin RA. Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park). 2012;26(3):290-301.

Show moreShow less

English / Filipino / French / Italian / Thai

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Edwin Posadas, MD